A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Study summary

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNivolumab and Daratumumab

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 23, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?20 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Bristol-Myers Squibb
Interventions being studied: Biological: Nivolumab; Biological: Daratumumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Patients with metastatic or advanced solid tumors
Women with histologically or cytologically confirmed triple negative breast carcinoma
Participants with histologically or cytologically confirmed pancreatic adenocarcinoma
Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)

Reasons someone may not be able to joinExclusion criteria

Active brain metastases or leptomeningeal metastases.
Any serious or uncontrolled medical disorder
Prior malignancy active within the previous 3 years Other protocol defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Pacific Shores Medical GroupLong Beach, California
University Of ColoradoAurora, Colorado
Moffitt Cancer CenterTampa, Florida
University Of MichiganAnn Arbor, Michigan
Providence Portland Medical CenterPortland, Oregon
Local InstitutionSt Leonards, New South Wales
Local InstitutionEdmonton
Local InstitutionLyon
Local InstitutionMarseille
Centre Paul StraussStrasbourg
Universitaetsklinikum Carl Gustav CarusDresden
Medizinische Universitaetsklinik FreiburgFreiburg im Breisgau

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 23, 2021. Always confirm current availability with the study team.

View original record ↗